

RESEARCH ARTICLE

Open Access

Screening toll-like receptor markers to predict latent tuberculosis infection and subsequent tuberculosis disease in a Chinese population

Linlin Wu^{1,2†}, Yi Hu^{1,2†}, Dange Li^{1,2}, Weili Jiang^{1,2} and Biao Xu^{1,2*}

Abstract

Background: We investigated whether polymorphisms in the toll-like receptor genes or gene–gene interactions are associated with susceptibility to latent tuberculosis infection (LTBI) or subsequent pulmonary tuberculosis (PTB) in a Chinese population.

Methods: Two matched case–control studies were undertaken. Previously reported polymorphisms in the toll-like receptors (TLRs) were compared between 422 healthy controls (HC) and 205 LTBI patients and between 205 LTBI patients and 109 PTB patients, to assess whether these polymorphisms and their interactions are associated with LTBI or PTB. A PCR-based restriction fragment length polymorphism analysis was used to detect genetic polymorphisms in the *TLR* genes. Nonparametric multifactor dimensionality reduction (MDR) was used to analyze the effects of interactions between complex disease genes and other genes or environmental factors.

Results: Sixteen markers in *TLR1*, *TLR2*, *TLR4*, *TLR6*, *TLR8*, *TLR9*, and *TIRAP* were detected. In *TLR2*, the frequencies of the CC genotype (OR = 2.262; 95% CI: 1.433–3.570) and C allele (OR = 1.566; 95% CI: 1.223–1.900) in single-nucleotide polymorphism (SNP) rs3804100 were significantly higher in the LTBI group than in the HC group, whereas the GA genotype of SNP rs5743708 was associated with PTB (OR = 6.087; 95% CI: 1.687–21.968). The frequencies of the GG genotype of SNP rs7873784 in *TLR4* (OR = 2.136; 95% CI: 1.312–3.478) and the CC genotype of rs3764879 in *TLR8* (OR = 1.982; 95% CI: 1.292–3.042) were also significantly higher in the PTB group than in the HC group. The TC genotype frequency of SNP rs5743836 in *TLR9* was significantly higher in the LTBI group than in the HC group (OR = 1.664; 95% CI: 1.201–2.306). An MDR analysis of gene–gene and gene–environment interactions identified three SNPs (rs10759932, rs7873784, and rs10759931) that predicted LTBI with 84% accuracy ($p = 0.0004$) and three SNPs (rs3804100, rs1898830, and rs10759931) that predicted PTB with 80% accuracy ($p = 0.0001$).

Conclusions: Our results suggest that genetic variation in *TLR2*, 4, 8 and 9, implicating *TLR*-related pathways affecting the innate immunity response, modulate LTBI and PTB susceptibility in Chinese.

Keywords: Toll-like receptors, Polymorphism, Tuberculosis, Latent tuberculosis infection, Susceptibility

Background

Mycobacterial infections remain a leading global health threat and are of major concern worldwide. The World Health Organization estimates that about one third of the world's population is infected with *Mycobacterium tuberculosis* (Mtb), and that about 1.4 million deaths

from tuberculosis (TB) occur each year [1]. Approximately 10% of individuals infected with Mtb develop active pulmonary disease, suggesting that there are differences in the susceptibility or resistance to disease development among individuals [2]. The results of twin [3] and family-based studies [4] support the role of genetics in the development of pulmonary TB (PTB). Furthermore, both human and mouse studies of mycobacterial infections have identified several potential TB-susceptibility or -resistance loci, including genes involved in toll-like receptor (TLR) signaling [5].

* Correspondence: bxu@shmu.edu.cn

†Equal contributors

¹Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China

²Key Laboratory of Public Health Safety (Fudan University), Ministry of Education, Shanghai, China

Bacterial infections typically result in the activation of the innate immune system as a first-line host defense mechanism. In humans, the TLRs contribute to this innate immune recognition of pathogens and shape the development of the adaptive immune response [5]. *Mtb* is initially recognized by TLR1, TLR2, TLR4, and TLR6, which then interact with the adaptor proteins MyD88 and toll-interleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP) to activate macrophages and dendritic cells [6,7]. TLRs play an integral role in the activation of the inflammatory cytokine signaling pathways and the adaptive immune response and as a result, have become biologically plausible candidate genes in studies of TB susceptibility [8]. Human genetic studies have also indicated that variants of the TLR pathway genes, including *TLR1* [9], *TLR2* [10,11], *TLR4* [12], and *TIRAP* [13], regulate the cellular immune response and may influence human susceptibility to *Mtb* in different populations [14]. However, these findings have not been replicated in different populations [15], and this lack of information has hindered the discovery of genetic susceptibility factors for this disease. Therefore, it is essential that we investigate whether polymorphic variants of the TLRs are associated with susceptibility to TB in different populations, especially in areas with a high TB burden.

In China, as in the rest of the world, TB is a significant public health problem. In Shanghai, TB has a prevalence of about 7,000 newly reported cases each year [16]. In a previous study, we reported that more than 30% of latent tuberculosis infections (LTBIs) cannot be explained by socio-demographic or clinical factors, which suggests a role for genetic factors [17]. The identification of high-risk individuals among recently exposed/infected individuals is extremely important in TB control programs established to reduce the disease burden in communities. There is strong functional evidence of a genetic component involving the TLRs in human susceptibility to TB. Therefore, in the present study, we examined PTB patients, LTBI subjects, and healthy controls (HC) from the Han population in Shanghai to test the association between 16 single-nucleotide polymorphisms (SNPs) of *TLR1*, *TLR2*, *TLR4*, *TLR6*, and *TLR9* and TB, to determine the possible association of these polymorphisms with disease susceptibility. We also investigated whether potential single- or multi-locus gene interactions or gene-environment interactions can predict the susceptibility to LTBI or PTB.

Methods

Subjects

The patients with PTB ($n = 109$), subjects with LTBI ($n = 225$), and HCs ($n = 422$) were recruited in the metropolitan area of Shanghai, one of the largest cities

in China. The incidence rate of TB in Shanghai in 2008 was 24.6 per 100,000 inhabitants, according to the municipal Center for Disease Prevention and Control (CDC).

Between 2011 and 2012, a total of 109 PTB patients were recruited from seven district CDCs, the facilities responsible for TB case management, in Shanghai. The patients included in this study were newly diagnosed with TB from sputum smear examinations for acid-fast bacilli and/or the culture of *Mtb* in the hospitals designated to treat TB in these districts. The exclusion criteria for patients included a positive serological test for human immunodeficiency virus (HIV) infection, organ transplantation, primary immunodeficiency, cancer, and treatment with immunosuppressive drugs, endocrine disorders such as diabetes, autoimmune or chronic renal disease, and pleural, miliary, or meningeal TB.

In total, 225 LTBI subjects and 422 healthy individuals were matched to the PTB patients by age, sex, and residency in the same district, were used as the control subjects in the present study. The individuals with LTBI were identified from the contacts of the participating PTB patients at the time of their diagnosis, and were defined as individuals who had had prolonged, frequent, or intense contact with a registered TB patient while he or she was infectious. The infectious period was defined based on the U.S. CDC guidelines [18]. The individuals with LTBI were ≥ 18 years old, HIV-seronegative, and had a positive TSPOT.*TB* result, with no evidence of active tuberculosis. The HCs were required to have a negative TSPOT.*TB* result, with no evidence of active tuberculosis. The specific criteria for the enrollment of the controls were the absence of pulmonary lesions on chest radiography and no history of TB disease. The exclusion criteria for HCs were the presence of a productive cough for more than 2 weeks, a previous history of TB, age < 15 years, and the presence of any clinical TB symptoms during the 2 years of clinical follow-up.

This study was approved by the Institutional Review Board of Fudan School of Public Health, Shanghai, and written informed consent was obtained from all the participants before blood sampling and a questionnaire-based interview.

Determination of sample size

The sample size and statistical power were calculated with the PASS software (version 12.0; NCSS LLS, Kaysville, UT), based on the following parameters: 80% power, $\alpha = 0.05$, a polymorphism prevalence of 10%, an allelic odds ratio for TB/LTBI of 2 compared with the control, and a match ratio of 2:1. Using these parameters and assumptions, the minimum sample size for each group was estimated to be 100 for the PTB group, 200 for the LTBI group, and 400 for the HC group.

Study procedures

At the time of recruitment, the contacts of the TB patients were interviewed by trained community health workers and immediately afterwards, a 5-ml blood sample was taken from each for the TSPOT.TB assay. Individuals with TB symptoms or with a positive TSPOT.TB result were examined for TB disease with a radiological examination. The contacts were asked for their sociodemographic and clinical information. Vaccination with the bacillus Calmette–Guérin (BCG) vaccine was verified by the interviewer, who confirmed the presence of BCG scars. All data were recorded on a standardized questionnaire by the trained health workers in the district CDCs.

Blood samples and DNA isolation

We collected 5 ml of peripheral blood from each participant into a glass tube containing potassium ethylenediaminetetraacetate. Genomic DNA was extracted with the salting-out protocol, using ammonium acetate [19]. The optical density of the DNA was measured on a Nanodrop spectrophotometer and 25–50 ng of DNA was used for each PCR.

Genotyping

A PCR-based restriction fragment length polymorphism (PCR–RFLP) analysis was performed for *TLR1* (SNP rs5743618), *TLR2* (rs3804099, rs5743708, rs3804100, and rs1898830), *TLR4* (rs4986790, rs4986791, rs11536889, rs10759932, rs7873784, and rs10759931), *TLR6* (rs5743810), *TLR8* (129) (rs3764879), *TLR9* (rs5743836 and rs1870884), and *TIRAP* (rs8177374) using genomic DNA isolated from peripheral blood leucocytes. The forward (F) and reverse (R) primer sequences (Sungon, Shanghai, China) (Additional file 1: Table S1), and restriction enzymes (New England Biolabs, Inc., Ipswich, MA) were used to detect the restriction digestion patterns for the different alleles [13,20,21]. The PCRs were performed under the appropriate cycling conditions: initial denaturation at 95°C for 5 min, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at the appropriate temperature for 30s, and extension at 72°C for 30 s, with a final extension at 72°C for 2 min. The annealing temperatures used were as follows: *TLR1*_1805: rs5743618 55°C; *TLR2*: rs3804099 65°C, rs5743708 65°C, rs3804100 63°C, and rs1898830 63°C; *TLR4*: rs4986790 56°C, rs4986791 56°C, rs11536889 54°C, rs10759932 54°C, rs7873784 55°C, and rs10759931 54°C; *TLR6*: rs5743810 52°C; *TLR8*_129: rs3764879 57°C; *TLR9*: rs5743836 59°C and rs1870884 60°C; and *TIRAP*: rs8177374 62°C. The PCR products were digested with the restriction endonucleases and the resulting fragments were separated by electrophoresis at 100 V on 3%

agarose gel containing 0.5 mg/ml ethidium bromide, and visualized under UV light.

Statistical analysis

The data were double entered on a spreadsheet (Microsoft Excel) and any discrepancies were checked with the original questionnaire data to ensure data consistency. The clinical and demographic characteristics were compared among the three groups (PTB, LTBI, and HC) with ANOVA for continuous variables and with the χ^2 test or Fisher's exact test for categorical variables. $p < 0.05$ was considered significant.

The allele and genotype frequencies of each polymorphism were determined by direct counting. The genotype distributions for each polymorphism were then tested for Hardy–Weinberg equilibrium values with the χ^2 test. The genotype and allele frequencies of the different groups were compared by calculating the odds ratios and 95% confidence intervals (CI) in a conditional logistic regression model (STATA version 9.0; College Station, TX). The linkage disequilibrium (LD) coefficients D' and r^2 were then calculated for the multi-locus polymorphisms studied in *TLR2* and *TLR4* to determine any co-segregation. The associations between the haplotypes and LTBI or TB were tested by calculating the logistic regression (adjustments) statistic and the corresponding p values and odds ratios (ORs) with 95% confidence intervals (CIs) using the SNPStats software (<http://bioinfo.iconcologia.net/SNPstats/>) [22]. The relationships between the *TLR* polymorphisms and the risk of PTB or LTBI were evaluated with the non-parametric MDR method [23]. Each best model was tested for its accuracy, cross-validation consistency, and significance level, determined with permutation testing, testing accuracy, and testing OR (95% CI) in the MDR analysis. Cross-validation consistency was defined as the number of cross-validation replicates (partitions) in which the same n -locus model was chosen as the best model (i.e., the number of replicates in which the classification error was minimized). Bonferroni corrections were applied to multiple comparisons. The level of significant was $p < 0.003125$ (0.05/16).

Results

Demographic data of the participants

The baseline characteristics of the study populations are summarized in Table 1. The age and sex distributions were very similar in all three groups. There was a significant difference between the PTB group and the LTBI group in the proportion of participants who had undergone BCG vaccination (87.2% versus 95.1%, respectively; $p = 0.01$).

Table 1 Characteristics of the study participants

Characteristics	TB (n = 109) No. (%)	LTBI (n = 225) No. (%)	HC (n = 422) No. (%)	χ^2 /ANOVA TB.vs.LTBI	χ^2 /ANOVA LTBI.vs.HC
Age, mean \pm SD, (yrs)	45 \pm 12.6	45 \pm 16.5	45 \pm 18.7	0.99	0.96
15~	16(14.7)	34(15.1)	63(14.9)	1.00	1.00
30~	27(24.8)	56(24.9)	105(24.9)		
45~	45(41.2)	92(40.9)	173(41.0)		
60~	21(19.3)	43(19.1)	81(19.2)		
Male	74(67.9)	152(67.6)	285(67.5)	0.951	1.000
BCG vaccination	95(87.2)	214(95.1)	405(96.0)	0.01 ^a	0.99

LTBI: latent tuberculosis infection; HC, health controls. SD, standard deviation.
^a $p < 0.05$.

SNP analysis

The genotype frequency distributions for all 16 SNPs investigated were consistent with Hardy–Weinberg equilibrium in all three groups, except SNPs rs3804100 ($p = 0.012$) and rs5743836 ($p = 0.023$) in the LTBI group, and rs7873784 in the LTBI ($p = 0.0328$) and PTB ($p = 0.0375$) groups.

The genotype and allele distributions were first compared between the HC and PTB groups. Compared with the HC group, the PTB group had significantly higher proportions of the GA genotype ($p = 0.002$; OR = 6.087; 95% CI: 1.687–21.968) and G allele ($p = 0.002$; OR = 5.943; 95% CI: 1.662–21.250) in rs5743708; the T allele in rs4986791 ($p = 0.002$; OR = 1.910; 95% CI: 1.260–2.896); the GG genotype in rs7873784 ($p = 0.002$; OR = 2.136; 95% CI: 1.312–3.478); the CC genotype in *TLR8*_129 ($p = 0.002$; OR = 1.982; 95% CI: 1.292–3.042); and the T allele in rs8177374 ($p < 0.001$; OR = 1.942; 95% CI: 1.238–3.048).

When we compared the genotype and allele distributions between the HC and LTBI groups, we found that the following genotypes and alleles showed significant associations with LTBI: rs3804100 (CC, $p < 0.001$; OR = 2.262; 95% CI = 1.433–3.570; C, $p < 0.001$; OR = 1.566; 95% CI = 1.233–1.990) and rs5743836 (TC, $p = 0.002$; OR = 1.664; 95% CI = 1.201–2.306).

There were no significant differences in the genotype or allele frequencies between the PTB patients and LTBI subjects. No other SNPs differed significantly in their genotypes (Table 2) or allele frequencies (Table 3) between the PTB patients, the LTBI subjects, and the HCs.

Haplotype analysis

Two haplotype block sets in *TLR2* and *TLR4* were identified with the haplotype analysis (Table 4). We selected four polymorphisms in *TLR2* and eight polymorphisms in *TLR4* after setting the threshold for the LD coefficient ($D' > 0.80$; Figure 1). The haplotype frequencies of *TLR4* were significantly higher in the PTB

group than in the LTBI group, for rs10759931/rs10759932 (AT, $p < 0.001$, OR = 2.00, 95% CI = 1.221–3.289) and rs4986790/rs4986791 (AT, $p < 0.001$, OR = 3.59, 95% CI = 1.570–8.565). However, the frequencies of the other haplotypes of *TLR2* and *TLR4* did not differ significantly among the three groups.

Gene–gene and gene–environment interactions evaluated with nonparametric MDR

After cross-validation and permutation tests of the gene–gene and gene–environment interactions in relation to the LTBI group, the best models included a one-marker model (rs5743836) with 56% balanced accuracy and 9/10 cross-validation consistency, a two-marker model (rs3804100, rs1898830) with 69% balanced accuracy and 10/10 cross-validation consistency, and a three-marker model (rs3804100, rs1898830, rs10759931) with 80% balanced accuracy and 10/10 cross-validation consistency (Table 5). The interaction dendrogram also indicated a synergistic effect between rs3804100 and rs10759931.

Regarding the role of these interactions in predicting PTB, we identified a one-marker model (BCG vaccination) that had maximum cross-validation consistency and a maximum prediction accuracy of 61%, a two-marker model (rs10759932, rs7873784) with 76% balanced accuracy and a cross-validation consistency of 100% in predicting PTB risk ($p = 0.0024$ based on 1000-fold permutation testing), and a three-marker model (rs10759932, rs7873784, rs10759931) with 84% balanced accuracy and a cross-validation consistency of 100% (Table 5). The interaction dendrogram shows the amount of information obtained about LTBI versus HC using MDR, and indicates a synergistic effect between rs10759932 and rs7873784.

Discussion

Shanghai is a city with a moderate incidence of TB, reaching 33.7 per 100,000 population in 1999 and 26.3 per 100,000 in 2000. Under these circumstances, all children born in Shanghai are routinely vaccinated with

Table 2 Distributions of toll-like receptor genotypes in the three groups

dbSNPs	Genotypes	Frequencies (No., %)				LTBI.vs.HC			TB.vs.LTBI			TB.vs.HC	
		HC (n = 422)	LTBI (n = 225)	TB (n = 109)	p	OR	95% CI	p	OR	95% CI	p	OR	95% CI
rs5743618	GG	2(0.5)	2(0.9)	1(0.9)	0.613	1.883	0.264-13.461	0.979	1.032	0.093-11.511	0.499	1.944	0.175-21.64
	TG	70(16.6)	23(10.2)	10(9.2)	0.028	0.573	0.347-0.946	0.763	0.887	0.407-1.936	0.054	0.508	0.252-1.022
	TT	350(82.9)	200(88.9)	98(89.9)	0.043	1.646	1.011-2.678	0.778	1.114	0.526-2.356	0.074	1.833	0.935-3.592
rs3804099	CC	51(12.1)	25(11.1)	9(8.3)	0.714	0.909	0.547-1.512	0.419	0.720	0.324-1.600	0.260	0.655	0.312-1.375
	TC	180(42.6)	95(42.2)	36(33.0)	0.916	0.982	0.708-1.363	0.107	0.675	0.418-1.089	0.068	0.663	0.426-1.033
	TT	191(45.3)	105(46.7)	64(58.7)	0.732	1.058	0.765-1.464	0.039	1.625	1.023-2.581	0.012	1.720	1.123-2.636
rs5743708	GA	4(0.9)	9(4.0)	6(5.5)	0.008	4.354	1.326-14.301	0.534	1.398	0.485-4.033	0.002	6.087	1.687-21.968 ^a
	GG	418(99.1)	216(96.0)	103(94.5)	0.008	0.229	0.051-0.836	0.534	0.715	0.221-2.513	0.002	0.164	0.046-0.593 ^a
rs3804100	CC	42(10.0)	45(20.0)	21(19.2)	<0.001	2.262	1.433-3.570 ^a	0.875	0.955	0.536-1.700	0.007	2.159	1.218-3.829
	TC	168(39.8)	90(40.0)	44(40.4)	0.963	1.008	0.724-1.402	0.949	1.015	0.637-1.619	0.916	1.023	0.666-1.572
	TT	212(50.2)	90(40.0)	44(40.4)	0.013	0.660	0.476-0.917	0.949	0.985	0.618-1.570	0.066	0.671	0.437-1.028
rs1898830	AA	142(33.6)	68(30.2)	33(30.3)	0.375	0.854	0.602-1.211	0.992	1.003	0.609-1.649	0.504	0.856	0.543-1.351
	AG	196(46.4)	113(50.2)	54(49.5)	0.360	1.163	0.842-1.608	0.907	0.973	0.616-1.538	0.564	1.132	0.743-1.725
	GG	84(20.0)	44(19.6)	22(20.2)	0.915	0.978	0.651-1.469	0.893	1.040	0.587-1.843	0.948	1.018	0.602-1.720
rs4986790	AA	346(82.0)	181(80.4)	77(70.6)	0.630	0.904	0.598-1.365	0.045	0.585	0.345-0.991	0.009	0.529	0.327-0.855
	AG	75(17.8)	42(18.7)	31(28.4)	0.778	1.062	0.699-1.613	0.043	1.732	1.094-3.050	0.013	1.839	1.132-2.987
	GG	1(0.2)	2(0.9)	1(0.9)	0.245	3.776	0.341-41.869	0.979	1.032	0.093-11.51	0.369	3.898	0.242-62.825
rs4986791	CC	342(81.0)	179(79.6)	74(67.9)	0.649	0.910	0.607-1.365	0.020	0.543	0.324-0.911	0.003	0.495	0.309-0.791
	CT	76(18.0)	43(19.1)	32(29.4)	0.730	1.076	0.710-1.629	0.035	1.759	1.036-2.987	0.009	1.892	1.169-3.061
	TT	4(1.0)	3(1.3)	3(2.7)	0.699	1.412	0.313-6.365	0.396	2.094	0.416-10.551	0.141	2.958	0.652-13.415
rs11536889	CC	34(8.1)	17(7.6)	10(9.2)	0.822	0.933	0.509-1.701	0.611	1.236	0.546-2.798	0.706	1.153	0.551-2.413
	GC	167(39.5)	86(38.2)	40(36.7)	0.737	0.945	0.678-1.317	0.787	0.937	0.584-1.504	0.583	0.885	0.573-1.368
	GG	221(52.4)	122(54.2)	59(54.1)	0.653	1.077	0.779-1.490	0.987	0.996	0.630-1.577	0.743	1.073	0.703-1.637
rs10759932	CC	42(10.0)	21(9.3)	5(4.5)	0.800	0.931	0.537-1.616	0.129	0.467	0.171-1.274	0.079	0.435	0.168-1.127
	TC	168(39.8)	90(40.0)	49(45.0)	0.963	1.008	0.724-1.402	0.389	1.225	0.772-1.945	0.330	1.235	0.807-1.888
	TT	212(50.2)	114(50.7)	55(50.5)	0.917	1.017	0.736-1.406	0.972	0.992	0.628-1.567	0.967	1.009	0.662-1.537
rs7873784	CC	29(6.9)	19(8.4)	7(6.4)	0.467	1.250	0.684-2.283	0.518	0.744	0.303-1.827	0.868	0.930	0.396-2.184
	GC	135(32.0)	57(25.4)	18(16.5)	0.078	0.721	0.501-1.037	0.070	0.583	0.324-1.050	0.001	0.421	0.244-0.726 ^a
	GG	258(61.1)	149(66.2)	84(77.1)	0.202	1.246	0.888-1.748	0.043	1.714	1.014-2.897	0.002	2.136	1.312-3.478 ^a
rs10759931	AA	143(33.9)	90(40.0)	44(40.4)	0.123	1.301	0.931-1.817	0.949	1.015	0.637-1.619	0.207	1.321	0.857-2.035
	AG	215(50.9)	113(50.2)	54(49.5)	0.860	0.971	0.703-1.343	0.907	0.973	0.616-1.538	0.793	0.945	0.620-1.440
	GG	64(15.2)	22(9.8)	11(10.1)	0.055	0.606	0.363-1.014	0.928	1.036	0.483-2.221	0.175	0.628	0.319-1.236

Table 2 Distributions of toll-like receptor genotypes in the three groups (Continued)

rs5743810	CT	12(2.8)	8(3.6)	5(4.6)	0.618	1.260	0.507-3.128	0.648	1.304	0.416-4.084	0.357	1.643	0.566-4.766
	TT	410(97.2)	217(96.4)	104(95.4)	0.618	0.790	0.293-2.276	0.648	0.773	0.215-3.057	0.357	0.609	0.210-1.766
TLR8_129	CC	133(31.5)	81(36.0)	52(47.7)	0.248	1.222	0.869-1.719	0.040	1.622	1.020-2.580	0.002	1.982	1.292-3.042 ^a
	CG	190(45.0)	96(42.7)	41(37.6)	0.565	0.909	0.656-1.259	0.379	0.810	0.507-1.295	0.164	0.736	0.478-1.134
	GG	99(23.5)	48(21.3)	16(14.7)	0.539	0.885	0.599-1.307	0.147	0.634	0.342-1.178	0.047	0.561	0.315-0.999
rs5743836	CC	25(5.9)	13(5.8)	6(5.5)	0.940	0.974	0.488-1.943	0.919	0.950	0.351-2.571	0.868	0.925	0.370-2.314
	TC	181(42.9)	125(55.5)	49(45.0)	0.002	1.664	1.201-2.306	0.069	0.653	0.412-1.035	0.698	1.087	0.712-1.661
	TT	216(51.2)	87(38.7)	54(49.5)	0.002	0.601	0.433-0.836	0.059	1.557	0.982-2.471	0.760	0.936	0.614-1.427
rs1870884	CC	3(0.7)	1(0.4)	0(0)	1.000	0.624	0.064-6.029	-	-	-	-	-	-
	TC	107(25.4)	56(24.9)	27(24.8)	0.896	0.976	0.672-1.417	0.981	0.994	0.585-1.687	0.900	0.969	0.596-1.578
	TT	312(73.9)	168(74.7)	82(75.2)	0.839	1.039	0.717-1.506	0.912	1.030	0.607-1.748	0.783	1.071	0.658-1.741
TIRAP_975	CC	313(74.2)	153(68.0)	61(56.0)	0.096	0.740	0.519-1.055	0.032	0.598	0.374-0.957	<0.001	0.443	0.286-0.685 ^a
	CT	97(23.0)	61(27.1)	40(36.7)	0.245	1.246	0.860-1.806	0.074	1.559	0.957-2.539	0.004	1.942	1.238-3.048
	TT	12(2.8)	11(4.9)	8(7.3)	0.181	1.756	0.762-4.046	0.365	1.541	0.601-3.949	0.028	2.706	1.078-6.796

PTB, pulmonary tuberculosis; LTBI, latent tuberculosis infection; HC, healthy control.

^a $p < 0.003125$ (0.05/16), the difference was statistically significant after correction for multiple testing (Bonferroni correction).

Table 3 Distribution of toll-like receptor alleles in the three groups

dbSNPS	Alleles	Frequencies (No., %)			LTBI.vs.HC			TB.vs.LTBI			TB.vs.HC		
		HC (n = 422)	LTBI (n = 225)	TB (n = 109)	p	OR	95% CI	p	OR	95% CI	p	OR	95% CI
TLR1_1805	G	74(8.7)	27(6.0)	12(5.5)	0.077	0.664	0.404-1.064	0.798	0.913	0.412-1.908	0.115	0.606	0.323-1.137
	T	770(91.3)	423(94.0)	206(94.5)	0.077	1.506	0.940-2.473	0.798	1.095	0.524-2.425	0.115	1.650	0.880-3.095
rs3804099	C	282(33.4)	145(32.2)	54(24.8)	0.665	0.947	0.736-1.217	0.048	0.693	0.471-1.012	0.014	0.656	0.467-0.921
	T	562(66.6)	305(67.8)	164(75.2)	0.665	1.055	0.859-1.244	0.048	1.443	0.988-2.124	0.014	1.524	1.086-2.139
rs5743708	A	840(99.5)	441(98.0)	212(96.8)	0.009	0.233	0.052-0.843	0.538	0.721	0.226-2.500	0.002	0.168	0.047-0.602 ^a
	G	4(0.5)	9(2.0)	6(3.2)	0.009	4.291	1.187-19.13	0.538	1.386	0.401-4.429	0.002	5.943	1.662-21.25 ^a
rs3804100	C	252(29.9)	180(40.0)	86(39.4)	<0.001	1.566	1.223-2.003 ^a	0.892	0.977	0.692-1.378	0.007	1.531	1.124-2.085
	T	592(70.1)	270(60.0)	132(60.0)	<0.001	0.638	0.499-0.818 ^a	0.892	1.023	0.742-1.387	0.007	0.653	0.480-0.890
rs1898830	A	480(56.9)	249(55.3)	120(55.0)	0.595	0.939	0.741-1/191	0.944	0.988	0.705-1.387	0.628	0.929	0.688-1.253
	G	364(43.1)	201(44.7)	98(45.0)	0.595	1.064	0.840-1.349	0.944	1.012	0.721-1.419	0.628	1.077	0.798-1.453
rs4986790	A	767(90.9)	404(89.8)	185(84.9)	0.521	0.882	0.591-1.325	0.065	0.638	0.385-1.068	0.009	0.563	0.363-0.872
	G	77(9.1)	46(10.2)	33(15.1)	0.521	1.133	0.754-1.691	0.065	1.567	0.937-2.595	0.009	1.777	1.146-2.754
rs4986791	C	760(90.0)	401(89.1)	180(82.6)	0.597	1.104	0.690-1.556	0.018	0.579	0.309-0.838 ^a	0.002	0.524	0.345-0.794 ^a
	T	84(10.0)	49(10.9)	38(17.4)	0.597	0.905	0.642-1.449	0.018	1.727	1.193-3.235 ^a	0.002	1.910	1.260-2.896 ^a
rs11536889	C	235(27.8)	120(26.7)	60(72.5)	0.651	0.942	0.721-1.228	0.815	1.044	0.712-1.523	0.925	0.984	0.705-1.373
	G	609(72.2)	330(73.3)	158(27.5)	0.651	1.061	0.814-1.386	0.815	0.958	0.657-1.404	0.925	1.016	0.728-1.418
rs10759932	C	252(29.9)	132(29.3)	59(27.1)	0.844	0.975	0.752-1.262	0.543	0.894	0.611-1.300	0.419	0.872	0.625-1.216
	T	592(70.1)	318(70.7)	159(72.9)	0.844	1.026	0.792-1.330	0.543	1.119	0.769-1.637	0.419	1.147	0.822-1.601
rs7873784	C	193(22.9)	95(21.1)	32(14.7)	0.469	0.903	0.713-1.270	0.047	0.643	0.401-0.912	0.008	1.632	1.084-2.456
	G	651(77.1)	355(78.9)	186(85.3)	0.469	1.107	0.787-1.403	0.047	1.555	1.017-2.494	0.008	0.613	0.407-0.923
rs10759931	A	501(59.4)	293(65.1)	142(65.1)	0.043	1.278	0.910-1.488	0.995	1.001	0.704-1.429	0.120	1.164	0.853-1.0589
	G	343(40.6)	157(34.9)	76(34.9)	0.043	0.782	0.672-1.099	0.995	0.999	0.700-1.421	0.120	0.859	0.629-1.173
rs5743810	C	12(1.4)	8(1.8)	5(2.3)	0.621	1.255	0.441-3.366	0.710	1.238	0.330-4.557	0.361	1.628	0.567-4.670
	T	832(98.6)	442(98.2)	213(97.7)	0.621	0.197	0.297-2.265	0.710	0.807	0.219-3.034	0.361	0.614	0.214-1.763
TLR_129	C	456(54.0)	258(57.3)	145(66.5)	0.255	1.143	0.774-1.251	0.023	1.478	0.674-1.335	0.001	0.932	0.689-1.261 ^a
	G	388(46.0)	192(42.7)	73(33.5)	0.255	0.875	0.799-1.292	0.023	0.676	0.749-1.484	0.001	1.073	0.793-1.451 ^a
rs5743836	C	231(27.4)	151(35.6)	61(28.0)	0.020	1.340	1.038-1.728	0.147	0.769	0.530-1.111	0.857	1.031	0.740-1.437
	T	613(72.6)	299(66.4)	157(72.0)	0.020	0.746	0.579-0.964	0.147	1.300	0.900-1.888	0.857	0.970	0.696-1.352
rs1870884	C	113(13.4)	58(12.9)	27(12.4)	0.800	0.957	0.669-1.359	0.855	0.955	0.563-1.591	0.696	0.914	0.584-1.433
	T	731(86.6)	392(87.1)	191(87.6)	0.800	1.044	0.736-1.494	0.855	1.047	0.629-1.777	0.696	1.094	0.698-1.713
TIRAP_975	C	723(85.7)	367(81.6)	162(74.3)	0.053	0.740	0.539-1.019	0.031	0.654	0.438-0.983 ^a	<0.001	0.484	0.338-0.694 ^a
	T	121(14.3)	83(18.4)	56(25.7)	0.053	1.351	0.981-1.855	0.031	1.535	1.017-2.286 ^a	<0.001	2.066	1.442-2.960 ^a

PTB, pulmonary tuberculosis; LTBI, latent tuberculosis infection; HC, healthy control.

^a $p < 0.003125$ (0.05/16), the difference was statistically significant after correction for multiple testing (Bonferroni correction).

the BCG vaccine soon after birth. Therefore, the tuberculin skin test has a high positive rate in China, but a positive tuberculin skin test does not conclusively distinguish between exposure *via* contact with *Mtb* and exposure *via* BCG vaccination. Therefore, in this study, we used the TSPOT.TB test to differentiate between LTBI subjects and individuals who were not infected with *Mtb*.

We examined 16 markers in seven TLR-related genes for their association with PTB or LTBI. These six *TLRs* were selected because there is strong biological evidence

of their roles in disease susceptibility. We observed statistically significant associations between *TLR2*, *TLR4*, and *TLR9* and susceptibility to PTB or LTBI.

The essential role of TLR2 against mycobacterial infection has been demonstrated *in vivo* by the rapid death [24,25] and higher *Mtb* burden in TLR2-deficient mice [25]. Therefore, it is reasonable to suggest that a subtle reduction in the expression of TLR2 could also make human more susceptible to the development of TB. In this study, the genotype and allele distributions of *TLR2*

Table 4 Haplotypes of the *TLR2* and *TLR4* genes and their distributions in the three groups

SNP marker	Haplotype	Frequency (No., %)			LTBI.vs.HC			PTB.vs.LTBI		
		HC (n = 422)	LTBI (n = 225)	PTB (n = 109)	P	OR	95% CI	P	OR	95% CI
rs3804099	CC	183(21.7)	95(21.1)	52(23.8)	0.812	0.97	0.722-1.289	0.422	1.17	0.779-1.747
rs3804100	CT	185(21.9)	85(18.9)	36(16.5)	0.201	0.83	0.615-1.114	0.455	0.85	0.537-1.326
	TC	103(12.2)	56(12.4)	18(8.3)	0.900	1.02	0.709-1.465	0.106	0.63	0.341-1.129
	TT	373(44.2)	214(47.6)	112(51.4)	0.247	1.15	0.904-1.450	0.354	1.17	0.832-1.632
rs10759931	AT	376(44.4)	204(45.3)	136(62.4)	0.787	1.03	0.735-1.447	<0.001 ^a	2.00	1.221-3.289
rs10759932	GT	218(25.7)	112(24.9)	22(10.1)	0.712	0.95	0.642-1.401	<0.001 ^a	0.34	0.153-0.694
	GC	156(18.5)	88(19.6)	6(2.8)	0.639	1.07	0.693-1.646	<0.001 ^a	0.12	0.022-0.379
	AC	94(11.4)	46(10.2)	54(24.7)	0.614	0.91	0.511-1.578	<0.001 ^a	2.89	1.496-5.596
rs4986790	AC	644(76.3)	353(78.4)	157(72.0)	0.383	1.13	0.852-1.505	0.067	0.71	0.481-1.046
rs4986791	AT	49(5.8)	11(2.4)	18(8.3)	0.006	0.39	0.180-0.784	0.001 ^a	3.59	1.570-8.565
	GC	33(3.9)	9(2.0)	0(0)	0.065	0.50	0.209-1.083	-	-	-
	GT	118(14.0)	77(17.1)	43(19.7)	0.134	1.27	0.915-1.755	0.409	1.19	0.766-1.833

PTB, pulmonary tuberculosis; LTBI, latent tuberculosis infection; HC, healthy control.

^a*p* < 0.003125 (0.05/16), the difference was statistically significant after correction for multiple testing (Bonferroni correction).

(rs3804100) differed significantly between the LTBI and HC groups, and this may be the first report of an association between rs3804100 and LTBI in China. These data suggest that a defective *TLR2* gene is a causative factor for increased susceptibility to LTBI and its subsequent progression to PTB disease. Therefore, the detection of this polymorphism among TB patients may provide important information in the assessment of their risk profiles for susceptibility to TB. We found that the Arg753Gln (rs5743708) polymorphism was a risk factor for TB in our Chinese population, which is slightly different from the results of other studies of Vietnamese patients with TB meningitis [26], Turkish patients with TB [11,27], and a Croatian Caucasian population [10]. This discrepancy may result from differences in the TB diagnostic criteria used, the genetics of the populations

studied, or differences in sample sizes or analytic approaches used.

Several investigators have studied the roles of *TLR4* genetic polymorphisms in major infectious diseases, including TB. In the present study, the rs7873784 polymorphism showed a strong association with PTB in our Chinese population. As reported previously in studies of Chinese [28], Indonesian [29], and Vietnamese populations [30], the 299Gly mutation was almost absent in the present study. However, the AG genotype of rs4986791 was related to PTB disease. This genetic variation in rs4986791 could alter the extracellular domain of the protein, which may modulate the interaction of ligands, such as lipopolysaccharide, with *TLR4* [31], leading to an impaired immune response and aggravated infection. The LD observed between the two *TLR4* variants (rs4986790




Figure 1 LD block structure in *TLR2* and *TLR4* and in the proximity of the gene in relation to LTBI (left) and PTB (right).

Table 5 MDR analysis of gene–gene and gene–environment interactions in relation to LTBI and PTB

Best model	Testing accuracy	Testing sensitivity	Testing OR	Testing χ^2	p	Cross-validation consistency
PTB.vs.LTBI						
BCG	0.61	0.70	1.76(1.067-2.903) ^a	4.958	0.026 ^a	6/10
rs10759932, rs7873784	0.76	0.72	3.29(2.096-8.283) ^a	9.253	0.0024 ^a	10/10
rs10759932, rs7873784, rs10759931	0.84	0.81	5.67(3.158-14.99) ^a	12.67	0.0004 ^a	10/10
LTBI.vs.HC						
rs5743836	0.56	0.55	1.68(1.189-2.365) ^a	8.76	0.0031 ^a	9/10
rs3804100, rs1898830	0.69	0.63	4.57(1.532-13.61) ^a	7.88	0.005 ^a	10/10
rs3804100, rs1898830, rs10759931	0.80	0.79	5.76(3.332-16.07) ^a	21.85	0.0001 ^a	10/10

PTB, pulmonary tuberculosis; LTBI, latent tuberculosis infection; HC, healthy control; MDR, multifactor dimensionality reduction.

^a $p < 0.05$.

and rs4986791) in the HC population ($D' = 0.82$) was also relatively weaker than the LD reported among European, Japanese, and other populations ($D' > 0.9$). This discrepancy could result from different environmental and pathogen-induced selection pressures, causing race-specific differences in the patterns of evolutionary distribution. The two cosegregating mutations, Thr399Ile and Asp299Gly, which occur in the ectoplasmic leucine-rich repeat domain of TLR4, are significantly associated with a reduced cytokine response to lipopolysaccharide stimulation [32] and increased susceptibility to a variety of infections [33,34] by affecting the extracellular domain of TLR4 [35]. We also found that SNP rs7873784, in the 3'-untranslated region (3'UTR) of *TLR4*, was significantly associated with PTB in the study population. The effect of the rs7873784 variant on TB has not been described before. However, rs7873784 was shown to be associated with a reduced risk of prostate cancer in an American population [36]. Together with the results of the present study, these findings imply that the 3'-UTR SNP rs7873784 potentially influences the development of various diseases, making it a good candidate functional SNP.

TLR9 is also known to play an important role in the activation of the innate immune system. It is the receptor for viral and bacterial CpG DNA motifs, and several studies have shown that the binding of TLR9 is necessary to drive the Th1 immune response [37,38]. In the present study, the *TLR9* polymorphism rs5743836 was associated with the risk of LTBI. This polymorphism in *TLR9* has been consistently associated with increased transcriptional activity [39,40], supporting the notion that rs5743836 enhances TLR9 function and increases susceptibility to LTBI.

TIRAP has two isoforms, both of which have a C-terminal TIR domain that mediates signals from TLR2 and TLR4. However, in the present study, no association was observed between the TIRAP polymorphism (975C/T) Ser180Leu and PTB or LTBI.

Because TLR6 mediates the recognition of lipopeptides when it forms a heterodimer with TLR2, we also examined

the *TLR6* 745C/T (rs5743810) polymorphism and observed a lower frequency of the C allele in the PTB and LTBI groups than in the HC group. However, the frequency was too low for a proper statistical evaluation, so the possible association between this *TLR6* polymorphism and human susceptibility to TB disease is yet to be confirmed in a Chinese population.

Several loci usually contribute to the phenotypes expressed in complex diseases, including TB. Therefore, it is important to identify gene–gene interactions (epistasis), because they may more accurately predict the risk of disease than single genes. In the present study, an MDR analysis was used to predict potential gene–gene and gene–environment interactions that may partly determine the complex phenotypes produced by *Mtb* pathogenesis. We found that rs3804100, rs1898830, and rs10759931 were associated with LTBI, whereas rs10759932, rs7873784, and rs10759931 were associated with PTB. These findings are consistent with the recently identified links between TLRs and the innate immune response to *Mtb*, i.e., the relationship between TLR signaling, the upregulated expression of the vitamin D receptor, and the vitamin-D-mediated killing of intracellular *Mtb* by the antimicrobial peptide cathelicidin [41]. However, these SNPs cannot be used to interpret the immunological findings that pertain to LTBI and subsequent PTB. Nonetheless, as noted above, they suggest that different cytokine pathways are important in LTBI and PTB. Further studies are required to determine whether these polymorphisms can account for this epidemiological finding.

The strength of this study was the differentiation of LTBI cases from HCs, which provided an opportunity to analyze the impact of TLR polymorphisms on the susceptibility to both LTBI and PTB. However, this study had some limitations. The individuals in the three groups were not matched for other risk factors (e.g., BCG vaccination), so their susceptibility to PTB and LTBI may have resulted not only from genetic factors. However, gene–gene and gene–environment interactions were evaluated in relation to LTBI and PTB. Furthermore, a few SNPs identified in

the LTBI and PTB groups deviated slightly from Hardy–Weinberg equilibrium in the HC group. However, these deviations were not significant ($p > 0.01$) and did not suggest significant genotyping errors. The observed deviations from Hardy–Weinberg equilibrium in the TLR polymorphisms in this Chinese population may indicate a functional effect, suggesting that more power may be necessary to observe such associations in China. We acknowledge that an important limitation of our study is the small sample size, which may also have a significant impact on observed statistical significance. This is the case of SNP rs5743708, where homozygotes for the minor allele were not detected and minimal heterozygotes' frequency fluctuations would obliterate the positive association result. Replication by independent studies with adequately powered sample size, will be necessary to confirm or refute our findings.

Conclusion

Taken together, our results suggest that polymorphisms in *TLR2* influence the risk of LTBI and subsequent PTB in the Chinese population, and that variations in *TLR4* and *TLR9* influence the risk of LTBI and PTB disease, respectively. Clarification of the precise roles that these genes play in TB susceptibility will require the isolation of functional variants of TLR2, TLR4, and TLR9 that can explain these variations. Epidemiological studies and basic and genetic research will extend our understanding of the critical determinants of host susceptibility to Mtb in different populations, and may provide new insights into the effects of genetic heterogeneity on the development of the different stages of TB.

Additional file

Additional file 1: Table S1. Primer sequences and restriction enzymes used for genotyping the studied TLR genes.

Abbreviations

TLR: Toll-like receptor; LTBI: Latent tuberculosis infection; TB: Tuberculosis; PTB: Pulmonary tuberculosis; PCR–RFLP: Polymerase chain reaction–restriction fragment length polymorphism; MDR: Multifactor dimensionality reduction; CDC: Center for Disease Prevention and Control.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

LW and YH participated in the study design, performed the statistical analysis, and drafted the manuscript. LW, YH, and DL performed the molecular genetic study. LW and YH performed the sequence alignments. YH, DL, and WJ collected the socio-demographic and clinical data. BX conceived the study, participated in its design and coordination, and helped to draft and finalize the manuscript. All the authors have read and approved the final manuscript.

Acknowledgments

This study was supported by the China National Key Project for Infectious Diseases (grant no. 2013ZX10004903), China Medical Board (no. 13–131), Young Investigator Grant from the Shanghai Health, Family Planning Commission (no. 20114Y034), and the National Natural Science Foundation of China (grant no. 81373063).

Received: 16 July 2014 Accepted: 20 March 2015

Published online: 01 April 2015

References

- Eurosurveillance Editorial T. ECDC and WHO/Europe joint report on tuberculosis surveillance and monitoring in Europe. *Euro Surveill.* 2014;19(11).
- Skamene E. Genetic control of susceptibility to infections with intracellular pathogens. *Pathol Biol.* 1998;46(9):689–92.
- Castrillon DM, Mejia SA, Hernandez JM, Robledo J. Pulmonary tuberculosis in a 4-month-old twin: hereditary versus environmental factors. *Int J Tuberc Lung Dis.* 2013;17(6):848–9.
- Sabri A, Grant AV, Cosker K, El Azbaoui S, Abid A, Rhorfi IA, et al. Association study of genes controlling IL-12-dependent IFN-gamma immunity: STAT4 alleles increase risk of pulmonary tuberculosis in Morocco. *J Infect Dis.* 2014;210(4):611–8.
- Misch EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. *Clin Sci.* 2008;114(5):347–60.
- Fujiwara N, Porcelli SA, Naka T, Yano I, Maeda S, Kuwata H, et al. Bacterial sphingophospholipids containing non-hydroxy fatty acid activate murine macrophages via Toll-like receptor 4 and stimulate bacterial clearance. *Biochim Biophys Acta.* 2013;1831(6):1177–84.
- He S, Liang Y, Shao F, Wang X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. *Proc Natl Acad Sci U S A.* 2011;108(50):20054–9.
- Qian C, Cao X. Regulation of Toll-like receptor signaling pathways in innate immune responses. *Ann N Y Acad Sci.* 2013;1283:67–74.
- Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, Musser JM. Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. *PLoS One.* 2007;2(12):e318.
- Etokebe GE, Skjeldal F, Nilsen N, Rodionov D, Knezevic J, Bulat-Kardum L, et al. Toll-like receptor 2 (P631H) mutant impairs membrane internalization and is a dominant negative allele. *Scand J Immunol.* 2010;71(5):369–81.
- Dalgic N, Tekin D, Kayaalti Z, Soylemezoglu T, Cakir E, Kilic B, et al. Arg753Gln polymorphism of the human Toll-like receptor 2 gene from infection to disease in pediatric tuberculosis. *Hum Immunol.* 2011;72(5):440–5.
- Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, Izagirre N, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. *Proc Natl Acad Sci U S A.* 2007;104(42):16645–50.
- Selvaraj P, Harishankar M, Singh B, Jawahar MS, Banurekha W. Toll-like receptor and TIRAP gene polymorphisms in pulmonary tuberculosis patients of South India. *Tuberculosis.* 2010;90(5):306–10.
- Arentz M, Hawn TR. Tuberculosis infection: insight from immunogenomics. *Drug Discov Today Dis Mech.* 2007;4(4):231–6.
- Berrington WR, Hawn TR. Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter? *Immunol Rev.* 2007;219:167–86.
- Yu W. Technical guidance group of the fifth national TB epidemiological survey. *Chin J Antituber.* 2012;34(8):485–508.
- Hu Y, Zhao Q, Graviss EA, Jiang W, Yuan Z, Xu B. Use of the T-SPOT.TB assay to screen latent tuberculosis infection among the TB contacts in Shanghai, China. *J Infect.* 2012;65(1):39–48.
- Thiel S, Holmskov U, Hviid L, Laursen SB, Jensenius JC. The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. *Clin Exp Immunol.* 1992;90(1):31–5.
- Rajalingam R, Mehra NK, Jain RC, Myneedu VP, Pande JN. Polymerase chain reaction–based sequence-specific oligonucleotide hybridization analysis of HLA class II antigens in pulmonary tuberculosis: relevance to chemotherapy and disease severity. *J Infect Dis.* 1996;173(3):669–76.
- Nilsson D, Andiappan AK, Hallden C, De Yun W, Sall T, Tim CF, et al. Toll-like receptor gene polymorphisms are associated with allergic rhinitis: a case control study. *BMC Med Genet.* 2012;13:66.

21. Folwaczny M, Glas J, Torok HP, Limbersky O, Folwaczny C. Toll-like receptor (TLR) 2 and 4 mutations in periodontal disease. *Clin Exp Immunol*. 2004;135(2):330–5.
22. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. *Bioinformatics*. 2006;22(15):1928–9.
23. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. *Am J Hum Genet*. 2001;69(1):138–47.
24. Reiling N, Holscher C, Fehrenbach A, Kroger S, Kirschning CJ, Goyert S, et al. Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with *Mycobacterium tuberculosis*. *J Immunol*. 2002;169(7):3480–4.
25. Drennan MB, Nicolle D, Quesniaux VJ, Jacobs M, Allie N, Mpagi J, et al. Toll-like receptor 2-deficient mice succumb to *Mycobacterium tuberculosis* infection. *Am J Pathol*. 2004;164(1):49–57.
26. Thuong NT, Hawn TR, Thwaites GE, Chau TT, Lan NT, Quy HT, et al. A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis. *Genes Immun*. 2007;8(5):422–8.
27. Ogus AC, Yoldas B, Ozdemir T, Uguz A, Olcen S, Keser I, et al. The Arg753Gln polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. *Eur Respir J*. 2004;23(2):219–23.
28. Xue Y, Zhao ZQ, Wang HJ, Jin L, Liu CP, Wang Y, et al. Toll-like receptors 2 and 4 gene polymorphisms in a southeastern Chinese population with tuberculosis. *Int J Immunogenet*. 2010;37(2):135–8.
29. Kobayashi K, Yuliwulandari R, Yanai H, Naka I, Lien LT, Hang NT, et al. Association of TLR polymorphisms with development of tuberculosis in Indonesian females. *Tissue Antigens*. 2012;79(3):190–7.
30. Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NT, Thuong NT, et al. The influence of host and bacterial genotype on the development of disseminated disease with *Mycobacterium tuberculosis*. *PLoS Pathog*. 2008;4(3):e1000034.
31. DeFranco AL, Crowley MT, Finn A, Hambleton J, Weinstein SL. The role of tyrosine kinases and map kinases in LPS-induced signaling. *Prog Clin Biol Res*. 1998;397:119–36.
32. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. *Nat Genet*. 2000;25(2):187–91.
33. Hawn TR, Verbon A, Janer M, Zhao LP, Beutler B, Aderem A. Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires' disease. *Proc Natl Acad Sci U S A*. 2005;102(7):2487–9.
34. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR, et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. *J Commun Dis*. 2006;38(3):230–45.
35. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. *Lancet Infect Dis*. 2005;5(3):156–64.
36. Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu FC, et al. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2005;14(11 Pt 1):2563–8.
37. Huang X, Barrett RP, McClellan SA, Hazlett LD. Silencing Toll-like receptor-9 in *Pseudomonas aeruginosa* keratitis. *Invest Ophthalmol Vis Sci*. 2005;46(11):4209–16.
38. Suzuki K, Suda T, Naito T, Ide K, Chida K, Nakamura H. Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA. *Am J Respir Crit Care Med*. 2005;171(7):707–13.
39. Ng MT, Van't Hof R, Crockett JC, Hope ME, Berry S, Thomson J, et al. Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9–1237 T/C polymorphism is associated with *Helicobacter pylori*-induced gastric disease. *Infect Immun*. 2010;78(3):1345–52.
40. Lange NE, Zhou X, Lasky-Su J, Himes BE, Lazarus R, Soto-Quiros M, et al. Comprehensive genetic assessment of a functional TLR9 promoter polymorphism: no replicable association with asthma or asthma-related phenotypes. *BMC Med Genet*. 2011;12:26.
41. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science*. 2006;311(5768):1770–3.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

